Oral Peptides: Can They Work? The Research So Far

The Barriers to Oral Peptide Delivery

The gastrointestinal tract presents three major obstacles to oral peptide absorption:

Chemical degradation: Stomach acid (pH 1-2) denatures peptide structure. Pepsin, trypsin, and chymotrypsin in the stomach and small intestine cleave peptide bonds. Most peptides are reduced to individual amino acids within minutes of ingestion.

Size exclusion: The intestinal epithelium is designed to absorb small molecules (amino acids, monosaccharides, fatty acids). Intact peptides are too large to pass through the tight junctions between epithelial cells or be efficiently transported by active mechanisms.

First-pass metabolism: Even if a peptide survives the gut and crosses the intestinal wall, it passes through the liver before reaching systemic circulation. Hepatic enzymes further degrade many peptide molecules.

SNAC and Oral Semaglutide

Novo Nordisk's oral semaglutide (Rybelsus) uses sodium salcaprozate (SNAC) as a permeation enhancer. SNAC creates a localized alkaline microenvironment around the tablet as it dissolves in the stomach, protecting semaglutide from acid degradation and transiently increasing permeability of the gastric epithelium.

The result: approximately 1% of the ingested dose reaches systemic circulation. That sounds terrible, and it is from an efficiency standpoint. But 1% of a sufficiently large dose is enough to achieve therapeutic plasma levels. The oral tablet contains 14 mg of semaglutide to achieve effects comparable to ~1 mg of the injectable form.

The tradeoff is strict dosing conditions: taken on an empty stomach with no more than 4 oz of plain water, no eating or drinking other liquids for 30 minutes. This limits patient compliance and convenience.

Small-Molecule GLP-1 Mimetics

If you can't get a peptide through the gut, why not make a small molecule that activates the same receptor? That's the approach behind orforglipron (Eli Lilly) and danuglipron (Pfizer) — non-peptide, orally bioavailable GLP-1 receptor agonists.

Orforglipron showed promising Phase 2 results: up to 14.7% weight loss at 36 weeks, with once-daily oral dosing and no food restrictions. If Phase 3 confirms these results, it could dramatically reduce manufacturing costs (small molecules are cheaper to produce than peptides) and eliminate injection-related barriers to patient adoption.

Nanoparticle Approaches

Encapsulating peptides in protective nanoparticles is another active research area. The nanoparticle protects the peptide from enzymatic degradation and facilitates transport across the intestinal epithelium.

Materials being investigated include chitosan nanoparticles (which open tight junctions), PLGA (poly lactic-co-glycolic acid) particles, liposomes, and solid lipid nanoparticles. Some approaches show 5-10% bioavailability in animal models — significantly better than SNAC, though still far from 100%.

The challenge is manufacturing complexity. Nanoparticle formulations are harder to scale, harder to characterize for consistency, and harder to regulate than simple tablets.

The Path Forward

True oral peptide delivery — achieving injectable-equivalent bioavailability from a simple pill — remains the holy grail of peptide therapeutics. The market incentive is enormous: oral delivery would expand the total addressable patient population by removing the injection barrier that limits uptake of even the most effective peptide drugs.

The most likely near-term outcome isn't a single breakthrough but a combination of approaches: improved permeation enhancers, more stable peptide analogs, and targeted delivery systems working together to push oral bioavailability from 1% toward 10-20%, which would be commercially transformative.